312611-92-0

Basic information

• Product Name: VK-28
• Synonyms: 5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]quinolin-8-ol
• CAS NO: 312611-92-0
• Molecular Formula: C16H21N3O2
• Molecular Weight: 287.361
• Mol File: 312611-92-0.mol
• Article Data: 2

Chemical Properties

• Melting Point: >230℃
• Appearance: off-white/solid
• Storage Temp.: 2-8°C
• Solubility: H2O: insoluble
• CAS DataBase Reference: VK-28(CAS DataBase Reference)
• NIST Chemistry Reference: VK-28(312611-92-0)
• EPA Substance Registry System: VK-28(312611-92-0)

Safety Data

• Hazard Codes: Xi
• Statements: 41
• Safety Statements: 26-39
• WGK Germany: 3
• Hazardous Substances Data: 312611-92-0(Hazardous Substances Data)

Usage

General Description

"VK-28" is a chemical compound that has been studied for its potential neuroprotective properties. It has been shown to have antioxidant and anti-inflammatory effects in animal models of neurological disorders, and may also have the ability to regulate dopamine levels in the brain. These properties make "VK-28" a potential candidate for the development of treatments for neurodegenerative diseases such as Parkinson's and Alzheimer's. Further research is needed to fully understand the mechanisms of action and potential therapeutic applications of this compound.

Upstream product

• 103-76-4 1-(2-hydroxyethyl)piperazine 
• 4053-45-6 5-chloromethyl-8-hydroxyquinoline hydrochloride 
• 148-24-3 8-quinolinol 

Relevant articles and documents

Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators

Use of a compound of formula (I), wherein R1 is H or hydrocarbyl; R2 is a hydrophobic radical; R3 is 3-(C2-C6)acyl-4-hydroxyphenyl, 3-hydroxyimino (C2-C6)-alkyl-4-hydroxyphenyl, or COOZ, wherein Z is H, (C1-C6) alkyl, aryl, aryl or ar(C1-C6) alkyl; and n is 1-20; and of a compound of formula (II), wherein R4 is (C1-C6) alkyl, cyano (C1-C6) alkyl, (C1-C6) alkoxy (C1-C6) alkyl or —CH2NR7R8, wherein R7 and R8, the same or different, is each H or (C1-C6) alkyl, or together with the N atom form a saturated or unsaturated 5-7 membered ring optionally containing a further heteroatom selected from N, O or S, the further N atom being optionally substituted, and either R5 is H and R6 is (C2-C6) acyl or hydroxyimino (C2-C6) alkyl, or R5 and R6 together with the phenyl ring form a quinoline, a 1,2,3,4-tetrahydroquinoline or a perhydroquinoline ring, for the preparation of pharmaceutical compositions for the treatment of Parkinson's disease or stroke.